Mallinckrodt says uvadex received approval in australia for use with therakos photopheresis system

Mallinckrodt announces uvadex® (methoxsalen) approved in australia for use with the therakos® cellex® photopheresis system for treatment of chronic graft versus host disease (cgvhd) and skin manifestations of cutaneous t-cell lymphoma (ctcl) in adults.mallinckrodt plc - uvadex has received regulatory approval in australia for extracorporeal administration with therakos photopheresis system.
MNK Ratings Summary
MNK Quant Ranking